Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Morgenstern

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Pediatric Blood & Cancer|May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid TumorsFilemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin J Lerman, Yimei Li, Cecilia Carlowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Cancer Discovery|February 10, 2021
Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK InhibitionBrittany B Campbell, Melissa A Galati, Simone C Stone, et al.
JAMA Oncology|October 17, 2024
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical TrialNathalie Gaspar, Giun-Yi Hung, Sandra J Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair DeficiencyAnirban Das, Uri Tabori, Lauren C Sambira Nahum, et al.
Pediatric Blood & Cancer|April 23, 2025
Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid LeukaemiaSeth E Karol, Seong L Khaw, C Michel Zwaan, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancerSteven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Pediatric Blood & Cancer|May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid TumorsFilemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin J Lerman, Yimei Li, Cecilia Carlowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Cancer Discovery|February 10, 2021
Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK InhibitionBrittany B Campbell, Melissa A Galati, Simone C Stone, et al.
JAMA Oncology|October 17, 2024
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical TrialNathalie Gaspar, Giun-Yi Hung, Sandra J Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair DeficiencyAnirban Das, Uri Tabori, Lauren C Sambira Nahum, et al.
Pediatric Blood & Cancer|April 23, 2025
Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid LeukaemiaSeth E Karol, Seong L Khaw, C Michel Zwaan, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancerSteven G DuBois, Lucas Moreno, Rochelle Bagatell, et al.
Pageof 15